Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, February 02, 2016
Catalent Pharma Solutions has announced that it will invest $4.6M to further expand its Singapore clinical supply facility by building new flexible GMP space for secondary packaging, doubling its ambient storage space, and quadrupling cold storage ...
read more
Catalent has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity.
read more
Monday, December 03, 2018
Catalent it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, Indiana, biologics manufacturing facility.
read more
Catalent announced that work is underway to expand integrated turnkey softgel capabilities at its facility in Eberbach, Germany.
read more
Catalent Pharma Solutions, a provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services, has announced the introduction of its Peel-ID™ label, a new standard...
read more
Wednesday, January 12, 2022
Catalent has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and advanced cell and gene therapies.
read more
Wednesday, August 12, 2020
Catalent announced that it has been approved by the FDA to produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy.
read more
Monday, November 01, 2021
Catalent, a global leader in clinical supply services, today announced the opening of a new facility in San Diego, in response to increased demand from pharmaceutical and biopharmaceutical customers for integrated development, clinical packaging, and...
read more
Catalent has expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions.
read more
Catalent announced the expansion of its UpTempo
SM platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.
read more
Wednesday, February 16, 2022
Catalent announced that it plans to expand its Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies, as well as additional secondary packaging ...
read more
Catalent has expanded its Singapore facility, which recently received GMP approval from the Health Science Authority, to provide secondary packaging and labeling capabilities.
read more
Catalent has invested a further $5 million at the company’s Somerset, New Jersey, drug development center of excellence to expand its OptiMelt® hot melt extrusion capabilities.
read more
Catalent announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.
read more
Catalent Pharma Solutions has completed an expansion project at its Kansas City, Missouri, facility to significantly increase controlled-temperature storage capabilities for its clinical supply business.
read more